Technologies

Flow technologies for the synthesis of chemical intermediates have great potential at the industrial level and the synthesis of nanoparticles (NPs) can speed up the development of new products. In this context, we could find the technology for the synthesis of NPs. The NPs (Au, Ag, or Pt) are synthesized in a single step and are functionalized with polymeric stabilizers (such as PVP, PVA, PEG, or others) or with thio-glycosidic fragments.

Chemical solution deposition of metal-organic precursors have favoured the research and development of thin films of simple and complex oxides such as Pb(Zr,Ti)O3, and Al2O3, up to their industrial application in pyroelectric and capacitor devices. Deposition methods used are spin-on and dip-coating. The advantages of the techniques are:

(i) low cost of equipment and chemicals

(ii) large area deposition

(iii) low crystallisation temperatures

We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.

The systems simulate, with high reproducibility, the conditions that occur in the different compartments of the gastrointestinal tracts and are promising to accurately mimic the digestive process, with the possibility to evaluate bioaccessibility and bioavailability. Moreover, the systems permit to study the synergic and reciprocal effects between the bioactive compounds characteristic of food and intestinal microbiota.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:

The full face mask adapts to the face of the user; it is used in the medical field where there may be close contact between a patient and a doctor and in all those areas of possible social overcrowding that, in case of a pandemic, may lead to the spread of a virus. To date, as the main means of containment and prevention of infection, are used masks made of fabric or equipped with filter that adhere to the face of the user in order to shield nose and mouth and / or filter the air inhaled and / or exhaled by the user.

This form describes a programmable, autonomous and stand-alone imaging system for the acquisition and processing of images containing subjects whose size is larger than 1cm (e.g. gelatinous zooplankton, fishes, litter, manufacts), form the seafloor or along the water column, in shallow or deep waters. It is capable to recognize and classify the image content through pattern recognition algorithms that combine computer vision and artificial intelligence methodologies.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.